An overview of arsenic trioxide-involved combined treatment algorithms for leukemia: basic concepts and clinical implications

[1]  C. Kumana,et al.  Acute promyelocytic leukaemia: population-based study of epidemiology and outcome with ATRA and oral-ATO from 1991 to 2021 , 2023, BMC Cancer.

[2]  Baofeng Yang,et al.  The involvement and therapeutic potential of lncRNA Kcnq1ot1/miR-34a-5p/Sirt1 pathway in arsenic trioxide-induced cardiotoxicity , 2023, Journal of Translational Medicine.

[3]  C. Kumana,et al.  Oral arsenic trioxide for treating acute promyelocytic leukaemia: Implications for its worldwide epidemiology and beyond , 2022, Frontiers in Oncology.

[4]  Xiao Sun,et al.  Oral Realgar-Indigo Naturalis Formula Treatment for Acute Promyelocytic Leukemia in Children: A Randomized, Control Clinical Trial , 2022, Evidence-based complementary and alternative medicine : eCAM.

[5]  Baofeng Yang,et al.  The whole transcriptome analysis and the circRNA-lncRNA network construction in arsenic trioxide-treated mice myocardium. , 2022, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[6]  Xue-Qun Luo,et al.  The comparison of plasma arsenic concentration and urinary arsenic excretion during treatment with Realgar-Indigo naturalis formula and arsenic trioxide in children with acute promyelocytic leukemia , 2022, Cancer Chemotherapy and Pharmacology.

[7]  K. Horibe,et al.  Gemtuzumab Ozogamicin Followed by Unrelated Cord Blood Transplantation With Reduced-intensity Conditioning for a Child With Refractory Acute Promyelocytic Leukemia. , 2022, Journal of pediatric hematology/oncology.

[8]  B. George,et al.  Real world data with concurrent retinoic acid and arsenic trioxide for the treatment of acute promyelocytic leukemia , 2022, Blood cancer journal.

[9]  A. Mosavat,et al.  Combination of auraptene and arsenic trioxide induces apoptosis and cellular accumulation in the subG1 phase in adult T-cell leukemia cells , 2021, Iranian journal of basic medical sciences.

[10]  S. Raimondi,et al.  Assessment of Arsenic Trioxide and All-trans Retinoic Acid for the Treatment of Pediatric Acute Promyelocytic Leukemia: A Report From the Children's Oncology Group AAML1331 Trial. , 2021, JAMA oncology.

[11]  Dingding Han,et al.  Curcumin Synergistically Enhances the Cytotoxicity of Arsenic Trioxide in U266 Cells by Increasing Arsenic Uptake , 2021, Evidence-based complementary and alternative medicine : eCAM.

[12]  J. Alves-Filho,et al.  The Combination of Gefitinib With ATRA and ATO Induces Myeloid Differentiation in Acute Promyelocytic Leukemia Resistant Cells , 2021, Frontiers in Oncology.

[13]  R. Schlenk,et al.  Long-term quality of life of patients with acute promyelocytic leukemia treated with arsenic trioxide vs chemotherapy , 2021, Blood advances.

[14]  Liping Qu,et al.  Safety and efficacy of Compound Huangdai Tablets combined with all-trans retinoic acid for treatment of acute promyelocytic leukemia: Clinical evidence and potential mechanisms , 2021, Chinese herbal medicines.

[15]  Ya-Zhen Qin,et al.  PML‐RARA transcript levels at the end of induction therapy are associated with prognosis in non‐high‐risk acute promyelocytic leukaemia with all‐trans retinoic acid plus arsenic in front‐line therapy: long‐term follow‐up of a single‐centre cohort study , 2021, British journal of haematology.

[16]  P. Chiusolo,et al.  Efficacy and Tolerability of First Line Arsenic Trioxide in Combination With All-Trans Retinoic Acid in Patients With Acute Promyelocytic Leukemia: Real Life Experience , 2021, Frontiers in Oncology.

[17]  F. Kalalinia,et al.  Effects of co-administration of arsenic trioxide and Schiff base oxovanadium complex on the induction of apoptosis in acute promyelocytic leukemia cells , 2021, BioMetals.

[18]  Limin Li,et al.  Arsenic Combined With All-Trans Retinoic Acid for Pediatric Acute Promyelocytic Leukemia: Report From the CCLG-APL2016 Protocol Study , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Yong-zhong Su,et al.  All-trans Retinoic Acid, Arsenic Trioxide, and Anthracycline-based Chemotherapy Improves Outcome in Newly Diagnosed Acute Promyelocytic Leukemia Regardless of FLT3-ITD Mutation Status , 2021, Current Medical Science.

[20]  Ya-Li Zhang,et al.  Arsenic trioxide-induced cell apoptosis and cell cycle arrest are potentiated by 1,25-dihydroxyvitamin D3 in human leukemia K562 cells , 2021, Oncology letters.

[21]  Jing Chen,et al.  Population Pharmacokinetics and Safety of Oral Tetra-Arsenic Tetra-Sulfide Formula in Pediatric Acute Promyelocytic Leukemia , 2021, Drug design, development and therapy.

[22]  Shengjin Fan,et al.  Characteristics of arsenic species in cerebrospinal fluid (CSF) of acute promyelocytic leukaemia (APL) patients treated with arsenic trioxide plus mannitol , 2021, British journal of clinical pharmacology.

[23]  S. Maqsood,et al.  An Outcome Analysis of Childhood Acute Promyelocytic Leukemia Treated with Atra and Arsenic Trioxide, and Limited Dose Anthracycline , 2021, Indian Journal of Hematology and Blood Transfusion.

[24]  Hsiao-Chuan Liu,et al.  Arsenic trioxide and all-trans retinoic acid in the treatment of children with newly diagnosed acute promyelocytic leukemia , 2021, Leukemia & lymphoma.

[25]  A. Sun,et al.  Safety and efficacy of different doses of anthracyclines combined with arsenic trioxide and all-trans retinoic acid in the treatment of de novo acute promyelocytic leukemia , 2021, Hematology.

[26]  J. Cheong,et al.  Arsenic trioxide synergistically promotes the antileukaemic activity of venetoclax by downregulating Mcl-1 in acute myeloid leukaemia cells , 2020, Experimental Hematology & Oncology.

[27]  P. Chinnakali,et al.  Walking a Tightrope: Dosage Modifications and Treatment Outcomes of All-Trans-Retinoic Acid, Arsenic Trioxide, and Daunorubicin for High-Risk Acute Promyelocytic Leukemia , 2020, JCO global oncology.

[28]  C. Kumana,et al.  Resurrection of Oral Arsenic Trioxide for Treating Acute Promyelocytic Leukaemia: A Historical Account From Bedside to Bench to Bedside , 2020, Frontiers in Oncology.

[29]  N. Patkar,et al.  Sequential Treatment of Arsenic Trioxide Followed by All Trans Retinoic Acid with Anthracyclines has Excellent Long-Term Cure in Acute Promyelocytic Leukemia , 2020, Indian Journal of Hematology and Blood Transfusion.

[30]  C. Kumana,et al.  Oral arsenic trioxide, all‐trans retinoic acid, and ascorbic acid maintenance after first complete remission in acute promyelocytic leukemia: Long‐term results and unique prognostic indicators , 2020, Cancer.

[31]  H. Rafatpanah,et al.  Synergy between parthenolide and arsenic trioxide in adult T-cell leukemia/lymphoma cells in vitro , 2020, Iranian journal of basic medical sciences.

[32]  Motohiro Kato,et al.  Successful Treatment With ATRA and Arsenic Trioxide for a Child With Down Syndrome and Acute Promyelocytic Leukemia. , 2020, Journal of pediatric hematology/oncology.

[33]  A. Jaleel,et al.  L-Ascorbic Acid and α-Tocopherol Synergistically Triggers Apoptosis Inducing Antileukemic Effects of Arsenic Trioxide via Oxidative Stress in Human Acute Promyelocytic Leukemia Cells , 2020, Frontiers in Oncology.

[34]  T. Zeng,et al.  Overexpression of the long noncoding RNA NEAT1 protects against As2O3-induced injury of cardiomyocyte by inhibiting the miR-124/NF-κB signaling pathway. , 2020, European review for medical and pharmacological sciences.

[35]  Li Liu,et al.  Treatment of non-high-risk acute promyelocytic leukemia with realgar-indigo naturalis formula (RIF) and all-trans retinoid acid (ATRA): study protocol for a randomized controlled trial , 2020, Trials.

[36]  M. Nikbakht,et al.  Effects of Sorafenib and Arsenic Trioxide on U937 and KG-1 Cell Lines: Apoptosis or Autophagy? , 2019, Cell journal.

[37]  J. Chen,et al.  A Novel Resveratrol-Arsenic Trioxide Combination Treatment Synergistically Induces Apoptosis of Adriamycin-Selected Drug-Resistant Leukemia K562 Cells , 2019, Journal of Cancer.

[38]  Jie Jin,et al.  Efficacy and safety of early switching to an outpatient therapy model using oral arsenic plus retinoic acid based-regimen in newly diagnosed acute promyelocytic leukemia. , 2019, Leukemia research.

[39]  M. Konopleva,et al.  Venetoclax-based therapies for acute myeloid leukemia. , 2019, Best practice & research. Clinical haematology.

[40]  Hongyu Li,et al.  A novel realgar-indigo naturalis formula more effectively induces apoptosis in NB4 cells. , 2019, Pakistan journal of pharmaceutical sciences.

[41]  R. Schlenk,et al.  Targeting FLT3 mutations in AML: review of current knowledge and evidence , 2019, Leukemia.

[42]  Yi Liu,et al.  Use of decitabine for patients with refractory or relapsed acute myeloid leukemia: a systematic review and meta-analysis , 2019, Hematology.

[43]  Ke Huang,et al.  Multicenter randomized trial of arsenic trioxide and Realgar‐Indigo naturalis formula in pediatric patients with acute promyelocytic leukemia: Interim results of the SCCLG‐APL clinical study , 2018, American journal of hematology.

[44]  M. Levis,et al.  Combination of ATO with FLT3 TKIs eliminates FLT3/ITD+ leukemia cells through reduced expression of FLT3 , 2018, Oncotarget.

[45]  H. Seo,et al.  Arsenic targets Pin1 and cooperates with retinoic acid to inhibit cancer-driving pathways and tumor-initiating cells , 2018, Nature Communications.

[46]  R. Pei,et al.  Salvianolic acid A, a novel PI3K/Akt inhibitor, induces cell apoptosis and suppresses tumor growth in acute myeloid leukemia , 2018, Leukemia & lymphoma.

[47]  Xiao-jun Huang,et al.  Oral arsenic plus retinoic acid versus intravenous arsenic plus retinoic acid for non-high-risk acute promyelocytic leukaemia: a non-inferiority, randomised phase 3 trial. , 2018, The Lancet. Oncology.

[48]  J. Gabrilove,et al.  Arsenic Trioxide and Sorafenib Induce Synthetic Lethality of FLT3-ITD Acute Myeloid Leukemia Cells , 2018, Molecular Cancer Therapeutics.

[49]  Ruiying Wang,et al.  Salvianolic Acid A Ameliorates Arsenic Trioxide-Induced Cardiotoxicity Through Decreasing Cardiac Mitochondrial Injury and Promotes Its Anticancer Activity , 2018, Front. Pharmacol..

[50]  A. Ghavamzadeh,et al.  Inhibitory Effects of Arsenic Trioxide and Thalidomide on Angiogenesis and Vascular Endothelial Growth Factor Expression in Leukemia Cells , 2018, Asian Pacific journal of cancer prevention : APJCP.

[51]  Hao Jiang,et al.  The impact of oral arsenic and all-trans-retinoic acid on coagulopathy in acute promyelocytic leukemia. , 2018, Leukemia research.

[52]  Zhiguo Wang,et al.  Downregulation of Long Non-Coding RNA Kcnq1ot1: An Important Mechanism of Arsenic Trioxide-Induced Long QT Syndrome , 2018, Cellular Physiology and Biochemistry.

[53]  S. Khochbin,et al.  Combination of arsenic trioxide and Dasatinib: a new strategy to treat Philadelphia chromosome‐positive acute lymphoblastic leukaemia , 2017, Journal of cellular and molecular medicine.

[54]  Sung-Hoon Kim,et al.  Auraptene Induces Apoptosis via Myeloid Cell Leukemia 1‐Mediated Activation of Caspases in PC3 and DU145 Prostate Cancer Cells , 2017, Phytotherapy research : PTR.

[55]  Jing-Gung Chung,et al.  Synergistic inhibition of leukemia WEHI-3 cell growth by arsenic trioxide and Hedyotis diffusa Willd extract in vitro and in vivo , 2017, Experimental and therapeutic medicine.

[56]  Yun Luo,et al.  Salvianolic Acid A Protects H9c2 Cells from Arsenic Trioxide-Induced Injury via Inhibition of the MAPK Signaling Pathway , 2017, Cellular Physiology and Biochemistry.

[57]  R. Liu,et al.  Effect and mechanism of Sorbus pohuashanensis (Hante) Hedl. flavonoids protect against arsenic trioxide-induced cardiotoxicity. , 2017, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[58]  E. Estey,et al.  Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab. , 2017, Blood.

[59]  Q. Yuan,et al.  [Combination of Homoharringtonine with Arsenic Trioxide Induces Apoptosis of Human Acute Myeloid Leukemia Cell Line U937]. , 2016, Zhongguo shi yan xue ye xue za zhi.

[60]  Tie-liang Ma,et al.  [Effect of Decitabine in Combination with Arsenic Trioxide on Prolife-ration and Apoptosis of Human Acute Myeloid Leukemia MV4-11 Cells]. , 2016, Zhongguo shi yan xue ye xue za zhi.

[61]  K. Suzukawa,et al.  Arsenic trioxide augments all-trans retinoic acid-induced differentiation of HL-60 cells. , 2016, Life sciences.

[62]  A. López-Guillermo,et al.  Transposon Mutagenesis Reveals Fludarabine Resistance Mechanisms in Chronic Lymphocytic Leukemia , 2016, Clinical Cancer Research.

[63]  K. Ando,et al.  Refractory acute promyelocytic leukemia successfully treated with combination therapy of arsenic trioxide and tamibarotene: A case report , 2016, Leukemia research reports.

[64]  Hao Jiang,et al.  Reduced medical costs and hospital days when using oral arsenic plus ATRA as the first-line treatment of acute promyelocytic leukemia. , 2015, Leukemia research.

[65]  Alina Klein,et al.  Acute promyelocytic leukemia with isochromosome 17q and cryptic PML-RARA successfully treated with all-trans retinoic acid and arsenic trioxide. , 2015, Cancer genetics.

[66]  F. Lo‐Coco,et al.  Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with all‐trans retinoic acid and arsenic trioxide , 2015, British journal of haematology.

[67]  R. Hills,et al.  Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial. , 2015, The Lancet. Oncology.

[68]  Yuan-qi Shi,et al.  Up‐regulation of miR‐21 and miR‐23a Contributes to As2O3‐induced hERG Channel Deficiency , 2015, Basic & clinical pharmacology & toxicology.

[69]  A. García-Pardo,et al.  Arsenic trioxide synergistically potentiates the cytotoxic effect of fludarabine in chronic lymphocytic leukemia cells by further inactivating the Akt and ERK signaling pathways. , 2015, Biochemical and biophysical research communications.

[70]  H. Dombret,et al.  Retinoic acid and arsenic trioxide trigger degradation of mutated NPM1, resulting in apoptosis of AML cells. , 2015, Blood.

[71]  R. Vrhovac,et al.  The mechanism of synergistic effects of arsenic trioxide and rapamycin in acute myeloid leukemia cell lines lacking typical t(15;17) translocation , 2015, International Journal of Hematology.

[72]  Wei Wang,et al.  The effect of nilotinib plus arsenic trioxide on the proliferation and differentiation of primary leukemic cells from patients with chronic myoloid leukemia in blast crisis , 2015, Cancer Cell International.

[73]  Xiao-jun Huang,et al.  Oral arsenic and retinoic acid for high-risk acute promyelocytic leukemia , 2014, Journal of Hematology & Oncology.

[74]  Dao Wang,et al.  The growth-inhibitory and apoptosis-inducing effect of deferoxamine combined with arsenic trioxide on HL-60 xenografts in nude mice. , 2014, Leukemia research.

[75]  Meng Chen,et al.  Arsenic Trioxide and Resveratrol Show Synergistic Anti-Leukemia Activity and Neutralized Cardiotoxicity , 2014, PloS one.

[76]  Kyoungha Kim,et al.  Src family kinase inhibitor PP2 enhances differentiation of acute promyelocytic leukemia cell line induced by combination of all-trans-retinoic acid and arsenic trioxide. , 2014, Leukemia research.

[77]  D. Douer,et al.  Adding ascorbic acid to arsenic trioxide produces limited benefit in patients with acute myeloid leukemia excluding acute promyelocytic leukemia , 2014, Annals of Hematology.

[78]  Li Fang-lin,et al.  Clinical Study on Prospective Efficacy of All-Trans Acid, Realgar-Indigo Naturalis Formula Combined with Chemotherapy as Maintenance Treatment of Acute Promyelocytic Leukemia , 2014, Evidence-based complementary and alternative medicine : eCAM.

[79]  L. Platanias,et al.  Resveratrol enhances the suppressive effects of arsenic trioxide on primitive leukemic progenitors , 2014, Cancer biology & therapy.

[80]  T. Yamauchi,et al.  BIMEL is a key effector molecule in oxidative stress-mediated apoptosis in acute myeloid leukemia cells when combined with arsenic trioxide and buthionine sulfoximine , 2014, BMC Cancer.

[81]  Saijuan Chen,et al.  Oral tetra-arsenic tetra-sulfide formula versus intravenous arsenic trioxide as first-line treatment of acute promyelocytic leukemia: a multicenter randomized controlled trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[82]  Yanzhu Zhu,et al.  The Protective Role of Resveratrol against Arsenic Trioxide-Induced Cardiotoxicity , 2013, Evidence-based complementary and alternative medicine : eCAM.

[83]  X. Chen,et al.  Upregulation of microRNA-1 and microRNA-133 contributes to arsenic-induced cardiac electrical remodeling. , 2013, International journal of cardiology.

[84]  Sang-Cheol Lee,et al.  Src Family Kinase Inhibitor PP2 Has Different Effects on All-Trans-Retinoic Acid or Arsenic Trioxide-Induced Differentiation of an Acute Promyelocytic Leukemia Cell Line , 2013, Cancer research and treatment : official journal of Korean Cancer Association.

[85]  Yi-jing Li,et al.  Resveratrol protects against arsenic trioxide-induced nephrotoxicity by facilitating arsenic metabolism and decreasing oxidative stress , 2013, Archives of Toxicology.

[86]  M. Stańczyk,et al.  Assessment of the involvement of oxidative stress and Mitogen-Activated Protein Kinase signaling pathways in the cytotoxic effects of arsenic trioxide and its combination with sulindac or its metabolites: sulindac sulfide and sulindac sulfone on human leukemic cell lines , 2012, Medical Oncology.

[87]  S. Lok,et al.  Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation. , 2012, Blood.

[88]  W. Au,et al.  Oral arsenic trioxide for relapsed acute promyelocytic leukemia in pediatric patients , 2012, Pediatric blood & cancer.

[89]  N. Nowak,et al.  Phase 1 study of arsenic trioxide, high‐dose cytarabine, and idarubicin to down‐regulate constitutive signal transducer and activator of transcription 3 activity in patients aged <60 years with acute myeloid leukemia , 2011, Cancer.

[90]  M. Stańczyk,et al.  Sulindac and its metabolites: sulindac sulfide and sulindac sulfone enhance cytotoxic effects of arsenic trioxide on leukemic cell lines. , 2011, Toxicology in vitro : an international journal published in association with BIBRA.

[91]  I. Bruns,et al.  The non-steroidal anti-inflammatory drugs Sulindac sulfide and Diclofenac induce apoptosis and differentiation in human acute myeloid leukemia cells through an AP-1 dependent pathway , 2011, Apoptosis.

[92]  Jai-Sing Yang,et al.  Extract of Hedyotis diffusa Willd influences murine leukemia WEHI-3 cells in vivo as well as promoting T- and B-cell proliferation in leukemic mice. , 2011, In vivo.

[93]  R. Ducas,et al.  Monomorphic ventricular tachycardia caused by arsenic trioxide therapy for acute promyelocytic leukaemia. , 2011, The journal of the Royal College of Physicians of Edinburgh.

[94]  Y. Min,et al.  Gefitinib enhances arsenic trioxide (AS2O3)-induced differentiation of acute promyelocytic leukemia cell line. , 2010, Leukemia research.

[95]  M. Terol,et al.  Induction of B-Chronic Lymphocytic Leukemia Cell Apoptosis by Arsenic Trioxide Involves Suppression of the Phosphoinositide 3-Kinase/Akt Survival Pathway via c-jun-NH2 Terminal Kinase Activation and PTEN Upregulation , 2010, Clinical Cancer Research.

[96]  Mario Petrini,et al.  Synergistic antiproliferative effect of arsenic trioxide combined with bortezomib in HL60 cell line and primary blasts from patients affected by myeloproliferative disorders. , 2010, Cancer genetics and cytogenetics.

[97]  Guoqiang Chen,et al.  Synergistic mitosis-arresting effects of arsenic trioxide and paclitaxel on human malignant lymphocytes. , 2010, Chemico-biological interactions.

[98]  A. Jordão,et al.  Apoptosis induction by (+)alpha-tocopheryl succinate in the absence or presence of all-trans retinoic acid and arsenic trioxide in NB4, NB4-R2 and primary APL cells. , 2009, Leukemia research.

[99]  Jiong Hu,et al.  Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia , 2009, Proceedings of the National Academy of Sciences.

[100]  S. Ogawa,et al.  Frequent genomic abnormalities in acute myeloid leukemia/myelodysplastic syndrome with normal karyotype , 2009, Haematologica.

[101]  S. Fröhling,et al.  Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B , 2009, Haematologica.

[102]  Jinhua Dong,et al.  N-(beta-Elemene-13-yl)tryptophan methyl ester induces apoptosis in human leukemia cells and synergizes with arsenic trioxide through a hydrogen peroxide dependent pathway. , 2008, Cancer letters.

[103]  Yanjie Lu,et al.  Arsenic trioxide-induced apoptosis in H9c2 cardiomyocytes: implications in cardiotoxicity. , 2008, Basic & clinical pharmacology & toxicology.

[104]  M. Czyz,et al.  Potentiation of arsenic trioxide cytotoxicity by Parthenolide and buthionine sulfoximine in murine and human leukemic cells , 2008, Cancer Chemotherapy and Pharmacology.

[105]  Zhen-yi Wang,et al.  Acute promyelocytic leukemia: from highly fatal to highly curable. , 2008, Blood.

[106]  R. Raddino,et al.  QT Prolongation: A Case of Arsenical Pericardial and Pleural Effusion , 2008, Cardiovascular Toxicology.

[107]  R. Greil,et al.  Arsenic trioxide induces apoptosis preferentially in B-CLL cells of patients with unfavourable prognostic factors including del17p13 , 2008, Journal of Molecular Medicine.

[108]  A. Redig,et al.  Regulatory Effects of Mammalian Target of Rapamycin-mediated Signals in the Generation of Arsenic Trioxide Responses* , 2008, Journal of Biological Chemistry.

[109]  U. Germing,et al.  Arsenic in the cerebrospinal fluid of a patient receiving arsenic trioxide for relapsed acute promyelocytic leukemia with CNS involvement. , 2007, Leukemia research.

[110]  R. Kwok,et al.  Chronic Arsenic Exposure and Cardiac Repolarization Abnormalities with QT Interval Prolongation in a Population-based Study , 2007, Environmental health perspectives.

[111]  Y. Kwong,et al.  Relationship of expression of aquaglyceroporin 9 with arsenic uptake and sensitivity in leukemia cells. , 2007, Blood.

[112]  S. Waxman,et al.  Buthionine sulfoximine enhancement of arsenic trioxide-induced apoptosis in leukemia and lymphoma cells is mediated via activation of c-Jun NH2-terminal kinase and up-regulation of death receptors. , 2006, Cancer research.

[113]  H. Dombret,et al.  Arsenic trioxide in patients with myelodysplastic syndromes: a phase II multicenter study. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[114]  J. Hainsworth,et al.  Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[115]  B. George,et al.  Hepatotoxicity profile of single agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia, its impact on clinical outcome and the effect of genetic polymorphisms on the incidence of hepatotoxicity , 2006, Leukemia.

[116]  R. Ohno,et al.  Two Cases of Acute Promyelocytic Leukemia Complicated by Torsade de Pointes during Arsenic Trioxide Therapy , 2006, International journal of hematology.

[117]  Charles Auffray,et al.  Coordination of intrinsic, extrinsic, and endoplasmic reticulum-mediated apoptosis by imatinib mesylate combined with arsenic trioxide in chronic myeloid leukemia. , 2005, Blood.

[118]  R. Ohno,et al.  Arsenic Trioxide Therapy in Relapsed or Refractory Japanese Patients with Acute Promyelocytic Leukemia: Updated Outcomes of the Phase II Study and Postremission Therapies , 2005, International Journal of Hematology.

[119]  L. Shih,et al.  19-Nor-1,25(OH)2D2 (a novel, noncalcemic vitamin D analogue), combined with arsenic trioxide, has potent antitumor activity against myeloid leukemia. , 2005, Cancer research.

[120]  A. Martelli,et al.  Phosphoinositide 3‐kinase/Akt involvement in arsenic trioxide resistance of human leukemia cells , 2005, Journal of cellular physiology.

[121]  S. Parmar,et al.  Phase II trial of arsenic trioxide in relapsed and refractory acute myeloid leukemia, secondary leukemia and/or newly diagnosed patients at least 65 years old. , 2004, Leukemia research.

[122]  D. Roden,et al.  Unusual Effects of a QT-Prolonging Drug, Arsenic Trioxide, on Cardiac Potassium Currents , 2003, Circulation.

[123]  C. Kumana,et al.  Oral arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia. , 2003, Blood.

[124]  J. Said,et al.  Vitamin D2 analog 19-nor-1,25-dihydroxyvitamin D2: antitumor activity against leukemia, myeloma, and colon cancer cells. , 2003, Journal of the National Cancer Institute.

[125]  S. Mader,et al.  Glutathione depletion overcomes resistance to arsenic trioxide in arsenic-resistant cell lines , 2003, Leukemia.

[126]  F. Giles,et al.  Phase II Study of Single Agent Paclitaxel in Adult Patients with Relapsed Acute Lymphocytic Leukemia , 2003, Investigational New Drugs.

[127]  R. Gallagher.  Retinoic acid resistance in acute promyelocytic leukemia , 2002, Leukemia.

[128]  W. Au,et al.  Arsenic trioxide‐ and idarubicin‐induced remissions in relapsed acute promyelocytic leukaemia: Clinicopathological and molecular features of a pilot study , 2001, American journal of hematology.

[129]  H. Gisslinger,et al.  Arsenic trioxide and ascorbic acid: synergy with potential implications for the treatment of acute myeloid leukaemia? , 2001, British journal of haematology.

[130]  M. Kuo,et al.  Arsenic trioxide sensitivity is associated with low level of glutathione in cancer cells , 1999, British Journal of Cancer.

[131]  Y. C. Chen,et al.  Acute and chronic arsenic poisoning associated with treatment of acute promyelocytic leukaemia , 1998, British journal of haematology.

[132]  T. Naoe,et al.  Treatment with a new synthetic retinoid, Am80, of acute promyelocytic leukemia relapsed from complete remission induced by all-trans retinoic acid. , 1997, Blood.

[133]  Wei Tang,et al.  Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. , 1997, Blood.

[134]  W. Plunkett,et al.  Natural killer cell activity in chronic lymphocytic leukemia patients treated with fludarabine , 1996, Cancer Chemotherapy and Pharmacology.

[135]  R. Herrmann,et al.  Oral idarubicin as single-agent treatment of acute nonlymphocytic leukemia in poor-risk patients. , 1987, Cancer treatment reports.

[136]  D. Bashash,et al.  CDK Blockade Using AT7519 Suppresses Acute Myeloid Leukemia Cell Survival through the Inhibition of Autophagy and Intensifies the Anti-leukemic Effect of Arsenic Trioxide , 2019, Iranian journal of pharmaceutical research : IJPR.

[137]  Jian-xun Liu,et al.  Salvianolic Acid A Protects Neonatal Cardiomyocytes Against Hypoxia/Reoxygenation-Induced Injury by Preserving Mitochondrial Function and Activating Akt/GSK-3β Signals , 2017, Chinese Journal of Integrative Medicine.

[138]  M. Yu,et al.  Resveratrol attenuates hepatotoxicity of rats exposed to arsenic trioxide. , 2013, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[139]  M. Levis,et al.  Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors , 2013, Leukemia.

[140]  H. Dombret,et al.  Extramedullary relapse in acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy , 2006, Leukemia.

[141]  S. Waxman,et al.  Glutathione- S -transferase (cid:1) inhibits As 2 O 3 -induced apoptosis in lymphoma cells: involvement of hydrogen peroxide catabolism , 2005 .

[142]  S. Waxman,et al.  Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system. , 1999, Blood.

[143]  K. Chansung,et al.  Complete Remission after Treatment of Acute Promuelocytic Leukemia with Arsenic Trioxide , 1999 .